Alnylam Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

$3B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Alnylam Pharmaceuticals's estimated annual revenue is currently $749.3M per year.(i)
  • Alnylam Pharmaceuticals received $445.6M in venture funding in January 2019.
  • Alnylam Pharmaceuticals's estimated revenue per employee is $267,898
  • Alnylam Pharmaceuticals's total funding is $3B.
  • Alnylam Pharmaceuticals's current valuation is $17.8B. (January 2022)

Employee Data

  • Alnylam Pharmaceuticals has 2797 Employees.(i)
  • Alnylam Pharmaceuticals grew their employee count by 7% last year.

Alnylam Pharmaceuticals's People

NameTitleEmail/Phone
1
CMO Management Drug Product Team Co-opReveal Email/Phone
2
Chief Accounting OfficerReveal Email/Phone
3
CEOReveal Email/Phone
4
Sr. Executive Assistant to the Chief Financial OfficerReveal Email/Phone
5
Senior Manager, CMO ManagementReveal Email/Phone
6
Executive Assistant to VP, General Manager UK & IrlReveal Email/Phone
7
Chief Staff to the Chief Commercial OfficerReveal Email/Phone
8
SVP, Chief Patent CounselReveal Email/Phone
9
VP, Investor Relations & Corporate CommunicationsReveal Email/Phone
10
SVPReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Alnylam Pharmaceuticals?

To those who say impossible, impractical, unrealistic, we say: CHALLENGE ACCEPTED. We are developing an innovative, entirely new class of medicines called RNAi therapeutics to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology - the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today's medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn't have to wait for hope. Alnylam is turning scientific possibility into reality - in August of 2018, the U.S. FDA approval of our first product ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. Our robust RNAi discovery platform and deep pipeline of investigational medicines includes three programs in late-stage clinical development and multiple programs in early-stage clinical development. We are a global and diverse company of more than 850 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Boston Globe Top Place to Work three years in a row! We are based in Cambridge, U.S., with offices in Zug, Switzerland, and Maidenhead, UK, and operations and employees across the U.S. and throughout Europe and Asia. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam) and YouTube. You can also sign up for email updates here: http://www.alnylam.com/signup-for-updates/

keywords:Biotechnology,Healthcare,Pharmaceuticals

$3B

Total Funding

2797

Number of Employees

$749.3M

Revenue (est)

7%

Employee Growth %

$17.8B

Valuation

N/A

Accelerator

Alnylam Pharmaceuticals News

2022-04-20 - Global RNAi Therapeutics Market Report 2022-2026 ...

Alnylam Pharmaceuticals Inc. Arrowhead Pharmaceuticals Inc. Arbutus Biopharma Corporation; Benitec Biopharma Ltd. Sirnaomics, Ltd. For more...

2022-04-06 - Alnylam Announces 3-Month Extension of Review Period for ...

Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran)...

2022-03-30 - Stellar Sales Growth Trend Makes Alnylam Pharmaceuticals Stock A Wise Bet

We think that Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for...

2019-09-08 - Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$297.7M2813-2%N/A
#2
$300M28729%N/A
#3
$1456.7M3153-4%N/A
#4
$300M32269%N/A
#5
N/A334052%N/A

Alnylam Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2002-08-02$15.0MBArticle
2003-07-09$24.6MLead Investor: MultiArticle
2003-09-10$UndisclosedStrategic InvestmenMerckArticle
2006-12-18$101.0MUndisclosedAmerica Securities LLCArticle
2012-02-17$86.9MUndisclosedArticle
2013-01-16$125.0MUndisclosedJP Morgan Securities LLC, Morgan Stanley & Co LLCArticle
2013-01-18$173.8MUndisclosedArticle
2014-01-14$700.0MUndisclosedGenzymeArticle
2015-01-22$517.5MUndisclosedJ.P. Morgan Securities LLCArticle
2017-05-25$413.2MUndisclosedBarclays Capital IncArticle
2017-11-14$675.0MUndisclosedGoldman Sachs & Co. LLCArticle
2019-01-16$445.6MUndisclosedBarclays Capital IncArticle